GeniSys

GeniSys is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for the treatment of cancer. The company's proprietary "pathotropic" (disease-seeking) nanotechnology platform enables the delivery of therapeutic genes directly to tumor sites while bypassing healthy tissue. Its lead candidate, Rexin-G, is a tumor-targeted retroviral vector designed to inhibit the cyclin G1 gene, which is overexpressed in many refractory cancers. GeniSys focuses on hard-to-treat malignancies, including pancreatic cancer, osteosarcoma, and soft tissue sarcoma. The company's approach aims to provide a more effective and less toxic alternative to conventional chemotherapy for patients with refractory solid tumors. GeniSys has conducted multiple clinical trials and received Orphan Drug and Fast Track designations from the FDA for its lead programs.